|Dr. Huw Jones||Chief Exec. Officer||224.4k||N/A||1960|
|Mr. Richard Anthony Moulson||CFO & Exec. Director||107.28k||N/A||1962|
|Dr. Helen Kuhlman||Chief Bus. Officer||N/A||N/A||N/A|
|Dr. Glen Clack FFPM, M.D.||Chief Medical Officer||N/A||N/A||N/A|
|Ms. Liz Jenkins||Regulatory Consultant||N/A||N/A||N/A|
|Prof. Albena Dinkova-Kostova||Independent Scientific Advisor||N/A||N/A||N/A|
|Prof. Giovanni Mann||Independent Scientific Advisor||N/A||N/A||N/A|
Evgen Pharma plc, a clinical stage drug development company, focuses in the development of sulforaphane-based compunds for the treatment of multiple diseases. Its core technology is Sulforadex, a means of synthesizing and stabilizing the naturally occurring compound sulforaphane. The company's lead product is SFX-01, a synthetic and stabilized form of sulforaphane that is in Phase II clinical trials for the treatment of metastatic breast cancer; in preclinical stage for glioma and glioblastoma; and in Phase IIb for treating acute respiratory infections. Evgen Pharma plc was founded in 2007 and is headquartered in Nether Alderley, the United Kingdom.
Evgen Pharma plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.